Mode
Text Size
Log in / Sign up

Narrative Review Suggests Electroacupuncture May Benefit NAFLD with Minimal Side Effects

Narrative Review Suggests Electroacupuncture May Benefit NAFLD with Minimal Side Effects
Photo by National Library of Medicine / Unsplash
Key Takeaway
Consider electroacupuncture as an experimental option for NAFLD, but recognize the evidence is preliminary and limited.

This is a narrative review that explores the potential role of electroacupuncture in the management of non-alcoholic fatty liver disease (NAFLD). The review synthesizes available evidence, primarily from preclinical and small clinical studies, to assess the efficacy and safety of this intervention.

The authors report that electroacupuncture may offer benefits for NAFLD, including improvements in liver function and metabolic parameters, though specific effect sizes are not provided. Importantly, the review notes that electroacupuncture is associated with minimal side effects, suggesting good tolerability.

However, the review acknowledges significant limitations: the evidence base is limited, the studies are heterogeneous, and the mechanisms are not fully understood. The narrative nature of the review means it is not a systematic synthesis, and no meta-analysis was performed.

Given these constraints, the findings should be considered hypothesis-generating rather than conclusive. Clinicians should not change practice based on this review alone, but it may inform future research directions. Larger, well-designed trials are needed to confirm any therapeutic role for electroacupuncture in NAFLD.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disorder globally, driven by increasing rates of obesity, insulin resistance, and metabolic dysfunction. In the absence of approved pharmacological therapies, electroacupuncture (EA) has garnered attention as a promising adjunctive intervention. This review synthesizes recent advances in understanding the mechanistic underpinnings and therapeutic potential of EA in NAFLD. We discuss how EA modulates hepatic lipid metabolism, insulin signaling, inflammation, fibrosis, and autophagy through key molecular pathways, including AMPK, SIRT1, PI3K/Akt, and NF-κB. Preclinical studies and emerging clinical trials indicate that EA effectively improves hepatic steatosis, metabolic parameters, and liver function with minimal side effects. Collectively, these findings underscore EA as a promising strategy for NAFLD treatment and highlight the need for further translational research.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.